Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
NCT06962007Recruiting
- Sponsor
- Wonkwang University Hospital
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (4 arms), sponsored by Wonkwang University Hospital. Primary endpoint: Incidence of Mouth Clenching After Neuromuscular Blockade Reversal at 10 minutes. Started Jul 2025; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT06962007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962007.